The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Long-term follow-up of real-world teclistamab therapy for R/R multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on the encouraging real-world outcomes with teclistamab therapy for relapsed/refractory (R/R) multiple myeloma (MM), highlighting that the safety and response rates in a global, real-world registry of patients with more than one year of follow-up are comparable to those seen in clinical trials. Dr Lin notes that these data support the value of teclistamab as a transformative therapy in standard-of-care practice. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
At the ASH 2024 meeting this year, the IMF immunotherapy data registry will be sharing longer-term follow-up of patients in the real-world standard of care practice really globally across centers from nine different countries with more than one year follow-up of the outcome of these patients who’ve received teclistamab, the BCMA-targeting bispecific, for multiple myeloma...
At the ASH 2024 meeting this year, the IMF immunotherapy data registry will be sharing longer-term follow-up of patients in the real-world standard of care practice really globally across centers from nine different countries with more than one year follow-up of the outcome of these patients who’ve received teclistamab, the BCMA-targeting bispecific, for multiple myeloma. What we’re seeing very encouragingly in this real-world patient population, where the majority of the patients would not have met eligibility criteria for the registration study, is that overall the safety outcome as well as in particular the clinical response, that we know can take time to deepen, appears to be quite on par with what we see in the clinical trial. So we are seeing a high percent of patients who are having a response, including CR, complete remission response as well. So that really speaks to the value of this very transformative therapy for our patients in standard of care practice.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
